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INTRODUCTION
Tissue valves are considered as ideal human cardiac valve
substitutes because they have excellent hemodynamic prop-
erties and chronic anticoagulants are not necessary. However,
the structural failure after prolonged usage prevents wides-
pread adaption of the tissue valves, especially for young age
groups (1). The reasons for the structural failure of the im-
planted tissue valves include repetitive mechanical wear, chron-
ic inflammatory response by glutaraldehyde fixation, and
pannus overgrowth. Recently, it has been found that the mam-
malian cell surface xenoantigen called α -Gal epitopes are still
present on the commercially available, glutaraldehyde fixed
tissue valves (2). Additionally it has been reported that pati-
ents who received these tissue valves exhibited increased lev-
els of natural anti-Gal antibody titers against α -Gal epitopes
(2). Therefore, it is believed that the animal immune response
may play an important role in structural damage of the com-
mercially available, glutaraldehyde fixed tissue valves.
The α -Gal epitopes on the mammalian cell surface trigger
a strong immune response, especially on endothelial cells,
resulting in a hyperacute rejection when we transplant mam-
malian organs to the primates (3). On the other hand, xeno-
antigen mediated immune response of the tissue valves were
not seriously considered until now because the valvular tis-
sue and pericardium of mammals were treated with gluta-
raldehyde to eradicate xenoantigenicity and potential risk of
xenozoonosis before using them to make tissue valves. How-
ever, after anti-Gal immune response in glutaraldehyde treat-
ed, commercially available tissue valves was recently observed,
there is a heightened concern in the immune response as a
cause of tissue valve structural failure.
In porcine aortic valvular tissue and pericardial tissue, it
became possible to stain α -Gal epitopes on the cell surface with
Griffonia simplicifolia isolectin B4 (GS-IB4) immunohisto-
chemical stain (4-6). And as green coffee bean α -galactosi-
dase is known to degrade α -Gal epitopes at the site of Galα
1-3Gal chain (7-9), it is possible that it could remove α -Gal
epitopes from those tissues. Previously we examined this pos-
sibility and reported that all α -Gal epitopes could be removed
from porcine valvular and pericardial cell surfaces using green
coffee bean α -galactosidase (10). Meanwhile, there are limita-
tions in cost effectiveness using green coffee bean α -galactosi-
dase in the commercial valve manufacturing process. There-
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Removal of Alpha-Gal Epitopes from Porcine Aortic Valve and 
Pericardium using Recombinant Human Alpha Galactosidase A
It has been reported that the immune response due to α -Gal epitopes is an impor-
tant factor in tissue valve failure. The elimination of the interaction between the natu-
ral anti-Gal antibodies and α -gal epitopes on the xenografts is a prerequisite to the
success of xenografts in humans. Previously, we reported that the green coffee
bean α -galactosidase could remove all α -Gal epitopes from cell surface of porcine
aortic valve and pericardial tissue, but it has limitations on cost effectiveness. In this
study we wanted to know whether the recently produced recombinant human α -
galactosidase A has the same effective enzymatic activity as green coffee bean α -
galactosidase in removing α -Gal epitopes from the same tissues. After treating fresh
porcine aortic valve and pericardial tissue with recombinant α -galactosidase A, each
sample was stained with Griffonia simplicifolia type I isolectin B4 indirect immunoper-
oxidase avidin-biotin technique. We then examined whether the α -Gal epitopes were
reduced or abolished in each consecutive concentration of recombinant α -galac-
tosidase A by comparing the degree of the Griffonia simplicifolia isolectin B4 stain-
ing. As a result, the recombinant α -galactosidase A could remove cell surface α -Gals
on porcine aortic valve and pericardial tissue as effectively as green coffee bean
α -galactosidase. 
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fore, we decided to investigate whether recently made, easi-
ly available recombinant human α -galactosidase A has same
enzymatic activity as green coffee bean α -galactosidase, and
whether the recombinant enzyme can effectively eradicate
α -Gal epitopes on the cell surface of porcine aortic valve and
pericardium. Additionally, we used standard indirect immu-
noperoxidase avidin-biotin technique in detecting α -Gals on
cell surface instead of previously used immunofluorescent
method.
MATERIALS AND METHODS
Staining α -Gal epitopes 
The heart and pericardium of pigs, aged 6-12 months, were
obtained from the local slaughter house and transported in
4℃ normal saline bag to our facility. After removing the
aortic valve and pericardial tissue, the tissue was thoroughly
washed with phosphate buffered saline (PBS). Samples of the
valve and pericardial tissue of 5×5 mm size were excised
and washed with PBS 3 times, 5 min each. The samples were
then immersed into 30% sucrose solution for preventing cell
rupture during freezing process. Next, the frozen sample were
sectioned and were mounted on the slides and fixed with cold
acetone for 10 min. After thorough washing in PBS 3 times,
for 5 min each, the sections were incubated on the slides in
1/500 diluted 500 mg/mL GS-IB4/biotin conjugates (Invit-
rogen, Carlsbad, CA, U.S.A.) at 37℃for 1 hr. Again sections
were washed as above. After blocking with 100 mL of 1%
bovine serum albumin (BSA)/PBS at 37℃ for 1 hr, sections
were washed as above. 100 mL of 5 mg/mL horseradishper-
oxidase (HRP) conjugated Streptavidin (HRP-SA) (Pierce
Biotechnology, Rockford, IL, U.S.A.) were applied to the slides
and incubated at 37℃for 1 hr. Thorough washing with PBS
was followed. Finally 3,3′ -diaminobenzidine (DAB) substrate
(DAB kit, Vector Lab., Burlingame, CA, U.S.A.) was applied
on the tissue slide for 5 min and the slides were observed under
mounting media. In this indirect immunoperoxidase avidin-
biotin technique using DAB as a substrate, brown staining
spots on the cell surface indicate GS-IB4 bound α -Gal epi-
topes.
Reacting with recombinant human α -galactosidase A
Recombinant human α -galactosidase A (Isu Abxis, Seoul,
Korea) made from chinese hamster ovary mammalian cells
were used in our experiment. 100 mM HEPES buffer solu-
tion at pH 5.0 was prepared, and used to make concentra-
tions of recombinant α -galactosidase A of 1.0, 5.0, 10.0 unit/
mL. The sliced aortic valve and pericardial tissue of pig of 5
×5 mm size were incubated with each of the solution for
24 hr under 4℃. After 24 hr, the tissues were washed with
PBS solution for 5 min 3 times, then immersed into 30%
sucrose solution. After then α -Gal epitopes on the enzyme
treated aortic valve and pericardial tissue were stained as des-
cribed above.
RESULTS
The images representing the distribution of α -Gal epitopes
on porcine aortic valve and pericardial tissue before and after
treatment with recombinant α -galactosidase A were obtained
via GS-IB4 conjugated indirect immunoperoxidase avidin-
biotin staining technique. After removing α -Gal epitopes
with consecutive incubations in 1.0, 5.0, 10.0 unit/mL of
recombinant α -galactosidase A, we noted that different degrees
of α -Gal epitopes were removed from the tissues according
to tissue type and enzyme concentration.
An enzyme concentration of 1.0 unit/mL was not enough
to completely eradicate the α -Gal epitopes from cell surface
of the aortic valve (Fig. 1). At 5.0 unit/mL, nearly all α -Gal
epitopes were removed from cell surface according to GS-IB4
Fig. 1. Aortic valve of a pig (×400): (A) before treatment, (B) after treatment with 1.0 unit/mL of recombinant α -galactosidase A. Many α -
Gal epitopes are still present on cell surface (arrow).
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staining (Fig. 2). There were no differences between 5.0 unit/
mL to 10.0 unit/mL enzyme concentrations in removing α -
Gal epitopes from the cell surface of the porcine aortic valve
(Fig. 3). Therefore, we could conclude that about 5.0 unit/mL
Fig. 2. Aortic valve of a pig (×400): (A) before treatment, (B) after treatment with 5.0 unit/mL of recombinant α -galactosidase A. α -Gal epi-
topes are nearly completely removed from cell surface.
A B
Fig. 3. Aortic valve of a pig (×400): (A) before treatment, (B) after treatment with 10.0 unit/mL of recombinant α -galactosidase A. No α -Gal
epitopes on cell surface. 
A B
Fig. 4. Pericardium of a pig (×400): (A) before treatment, (B) after treatment with 1.0 unit/mL of recombinant α -galactosidase A. Many α -Gal
epitopes are still present on cell surface (arrow). 
A B
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concentration of recombinant α -galactosidase A with reac-
tion conditions of pH 5.0, temperature 4℃, 24 hr of incu-
bation was enough to remove all α -Gal epitopes from cell
surface of porcine aortic valve. On the other hand, in porcine
pericardial tissue, enzyme concentration of 1.0 unit/mL (Fig.
4) and even 5.0 unit/mL (Fig. 5) were not enough to com-
pletely eradicate α -Gal epitopes from cell surface. At 10.0
unit/mL, all the α -Gal epitopes from the cell surface of peri-
cardium were removed according to GS-IB4 staining (Fig. 6).
Therefore, in porcine pericardial tissue, the more recombinant
α -galactosidase A was needed to remove all α -Gal epitopes
from cell surface than that needed in aortic valve. This find-
ing is in accordance with the result of our previous study (10).
DISCUSSION
Improving the durability of the tissue valves are crucial,
not only for the children-adolescent patients but also for the
increasing number of elderly patients receiving tissue valves
in the aortic valve position. Recently, nearly 70% of aortic
valve replacement in the patients older than 70 yr were done
using tissue valves (11, 12). The tissue valve degeneration
have been caused by degenerative calcification, glutaralde-
hyde related calcification (13), mechanical wear, and pannus
overgrowth. Recently it was shown that α -Gal epitopes, res-
ponsible for hyperacute rejection in xenotransplantation, were
still present on glutaraldehyde fixed, commercially available
tissue valves. Also an increased number of anti-Gal antibod-
ies in the patients who received those tissue valves was noted
(2). Therefore, it is possible that the α -Gal-anti-Gal immune
reaction may play a certain role in valve calcification and deg-
radation after tissue valve replacement and removing α -Gals
from the surface of the tissue valves can improve the dura-
bility of the tissue valves. Until now two methods of remov-
ing α -Gal epitopes from porcine tissues are available. One is
enzymatic removal using α -galactosidase (7-9). The other is
creating an α -1,3 galactosyltransferase deficient pigs (α -Gal
Fig. 5. Pericardium of a pig (×400): (A) before treatment, (B) after treatment with 5.0 unit/mL of recombinant α -galactosidase A. Some α -
Gal epitopes are still present on cell surface (arrow). 
A B
Fig. 6. Pericardium of a pig (×400): (A) before treatment, (B) after treatment with 10.0 unit/mL of recombinant α -galactosidase A. α -Gal epi-
topes are nearly completely removed from cell surface.
A B
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knockout pigs) with the recently well established animal
cloning methods (14, 15). Using α -Gal knockout pigs is the-
oretically ideal and we can use organs and tissues without a
fear of hyperacute rejection. But it is not feasible now. α -Gal
degrading enzyme is easy to use and inexpensive. However,
in the enzyme treated organs α -Gal reappears after a certain
time (9). To remove α -Gal epitopes from cardiac valvular and
pericardial tissues, enzymatic removal is feasible because no
α -Gal reappearance occurs in such tissues. So, we used enzy-
matic method to remove α -Gals from cell surface of the tis-
sues.
Green coffee bean α -galactosidase is a plant enzyme which
eradicates the xenoantigenicity of α -Gal by cleaving Galα 1-
3Gal chain of α -Gal(Galα 1-3Galβ 1-4GlcNAc) (7-9). Previ-
ously we reported that α -Gal epitopes could be removed from
porcine aortic valve and pericardial tissue using green coffee
bean α -galactosidase (Sigma, St. Louis, MO, U.S.A.) (10).
But green coffee bean α -galactosidase is not cost effective for
the commercial valve manufacturing process.
Fabry disease, which exhibits X-linked genetic trait, is a
congenital human α -galactosidase A deficiency representing
early peripheral neuropathy, late chronic renal failure, coro-
nary artery disease and cerebral vascular disease. It is well
known that enzyme replacement therapy (ERT) using recom-
binant human α -galactosidase A is helpful for those patients
(16, 17). Recently, recombinant human α -galactosidase A
with Chinese hamster ovary mammalian cell expression sys-
tem was developed for ERT in Fabry disease. This enzyme
cleaves exactly the same site of α -Gal as green coffee bean α -
galactosidase (10), which can also applied in removing α -Gal
epitopes from cell surface of porcine aortic valve and pericar-
dial tissue. In aortic valve, the recombinant enzyme of 5.0
unit/mL concentration could remove almost all α -Gals under
reaction condition of pH 5.0, temperature 4℃, 24 hr of incu-
bation. In pericardial tissue, 10.0 unit/mL concentration of
the recombinant enzyme was needed.
There are several methods which can detect α -Gal epitopes
in the tissues. First and most popular is detecting α -Gals with
Griffonia simplicifolia type I isolectin B4 which highly specif-
ically bind to cell surface α -Gals (4-6). Others are using mon-
oclonal antibody M86 made by Galili (18), using FITC la-
beled anti-immunoglobulin M, anti-immunoglobulin G
which are species specific secondary antibodies derived from
anti-Gal immunoglobulin M and anti-Gal immunoglobu-
lin G, respectively (7). We previously reported that all three
methods of α -Gal detection technique must be simultaneous-
ly used to prove complete removal of α -Gals from cell sur-
face (10). But in this study we intended to prove only that
recombinant human α -galactosidase A can just as effectively
remove α -Gal epitopes from porcine aortic valve and pericar-
dial tissue as green coffee bean α -galactosidase. In other words,
we did not intend to prove the completeness of removal of
α -Gals from cell surface of those tissues. So, we did not use
the three methods simultaneously. In this study we used stan-
dard indirect immunoperoxidase avidin-biotin technique in-
stead of previously used FITC labeled immunofluorescent
method in detecting GS-IB4 bound to α -Gals on cell sur-
face. We used DAB (DAB kit, Vector Lab., Burlingame, CA,
U.S.A.) as a substrate for the indirect immunoperoxidase
avidin-biotin staining method and as a result, the cell sur-
face α -Gals exhibit brown colors. In this way we could exam-
ine the distribution of α -Gals on cell surface more precisely
and avoid autofluorescence issues of FITC.
In this study, we conclude that α -Gal epitopes can be re-
moved from the porcine aortic valve and pericardial tissue
using the recombinant human α -galactosidase A as effective-
ly as using green coffee bean α -galactosidase. Thus with this
recombinant enzyme, α -Gal deficient, more durable tissue
valves can be made more economically in the future. 
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